▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1963 by analyst upside · 2026-09-27
ALKS
Alkermes plc
Healthcare · Market Cap $7B · P/E 107.5x
ANALYST PRICE TARGET
+38.4%
implied upside to consensus target
Current Price $40.85
Consensus Target $56.56
Bull Target $83.0
Bear Target $38.0
Analysts Covering 18
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
4
Sell
1
52-Week Low $27.0
52-Week High $55.67
YTD Return +44.6%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) 107.5x
Forward P/E 22.6x
EPS (TTM) $0.38
PEG Ratio 1.96
Dividend Yield N/A
Revenue (TTM) $1.7B
Profit Margin 4.0%
52-WEEK RANGE
52-Week Low $27.0
52-Week High $55.67
Current Price $40.85
Bear Target $38.0
Bull Target $83.0
● Now $40.85 ● Target $56.56
TRADING DATA
Avg Volume 1.8M
YTD Return +44.6%
Analyst Count 18
Consensus Buy
Upside to Target +38.4%
Last Updated 2026-09-27

ANALYST SUMMARY

Alkermes plc (ALKS) is currently trading at $40.85 with a Wall Street consensus price target of $56.56, implying potential upside of 38.4% over the next 12 months. 18 analysts currently cover ALKS, with a consensus rating of Buy - 72% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $83.0, while the most cautious has a target of $38.0.

ALKS operates in the Healthcare sector with a market capitalisation of $7B. The stock is up 44.6% year-to-date and is currently trading near the lower end of its 52-week range of $27.0 – $55.67.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ALKS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital reit
Outperform → Outperform 2026-09-22 Building track record
Baird - Reiterated
Outperform → Outperform 2026-09-22 Building track record
Needham reit
Buy → Buy 2026-09-21 20% win rate (5 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-07-29 43% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-07-29 Building track record
Piper Sandler reit
Overweight → Overweight 2026-07-28 14% win rate (7 calls)
Stifel reit
Buy → Buy 2026-07-20 Building track record
Needham - Reiterated
Buy → Buy 2026-07-13 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
22/30
Consensus clarity
8/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →